Lo Jean C Y, Lea Walters E, Wolk Brian
Loma Linda University Medical Center, Department of Emergency Medicine, Loma Linda, California.
Clin Pract Cases Emerg Med. 2024 Aug;8(3):219-221. doi: 10.5811/cpcem.6583.
Pit viper envenomation may cause coagulopathy. The coagulopathy has been treated with crotalidae polyvalent immune fragment antigen-binding (Fab) ovine antivenom for the last few decades in the United States and usually corrects the acute coagulopathy within hours. Days after receiving Fab, coagulopathy may recur in approximately half of the patients. Another divalent antivenom, crotalidae immune F(ab') (equine)-F(ab')-was approved by the US Food and Drug Administration for the treatment of pit viper envenomation. F(ab') is composed of two linked antigen-binding fragments of immunoglobulin G. Several studies have demonstrated that F(ab') is less likely to be associated with recurrence. There is no reported case of F(ab')-associated late coagulopathy in very young patients. We report the first case of recurrence associated with F(ab') use in a preschool-age child.
A preschool-age male developed leg swelling and hypofibrinogenemia after rattlesnake envenomation. F(ab') was administered to stabilize the leg edema and to correct the hypofibrinogenemia. The patient improved clinically and was discharged on hospital day five. Seven days after the rattlesnake envenomation, he returned to the emergency department as instructed. Laboratory data revealed recurrent hypofibrinogenemia.
There are two antivenoms available in the US to treat crotalid envenomation, Fab and F(ab'). F(ab') is less likely to be associated with recurrent coagulopathy in comparison to Fab. We report the first case of recurrence associated with F(ab') in a preschool-age child. It is important that the emergency physician be aware of potential F(ab')-associated recurrent coagulopathy. Adult and pediatric patients may need to follow up to be evaluated for hypofibrinogenemia and/or thrombocytopenia after receiving F(ab').
蝰蛇咬伤可能导致凝血病。在美国,过去几十年一直使用抗蛇毒血清(Fab)来治疗凝血病,通常能在数小时内纠正急性凝血病。在接受Fab治疗数天后,约一半的患者凝血病可能复发。另一种二价抗蛇毒血清,即抗蛇毒免疫F(ab')(马源)-F(ab'),已获美国食品药品监督管理局批准用于治疗蝰蛇咬伤。F(ab')由两个相连的免疫球蛋白G抗原结合片段组成。多项研究表明,F(ab')与复发的关联较小。尚无关于F(ab')在非常年幼患者中导致迟发性凝血病的报道。我们报告了首例在学龄前儿童中使用F(ab')后出现复发的病例。
一名学龄前男性被响尾蛇咬伤后出现腿部肿胀和纤维蛋白原血症。给予F(ab')以稳定腿部水肿并纠正纤维蛋白原血症。患者临床症状改善,于住院第5天出院。响尾蛇咬伤7天后,他按指示返回急诊科。实验室数据显示纤维蛋白原血症复发。
美国有两种抗蛇毒血清可用于治疗蝰蛇咬伤,即Fab和F(ab')。与Fab相比,F(ab')与凝血病复发的关联较小。我们报告了首例在学龄前儿童中使用F(ab')后出现复发的病例。急诊医生应意识到F(ab')可能导致的复发性凝血病,这一点很重要。成年和儿科患者在接受F(ab')治疗后可能需要随访,以评估是否存在纤维蛋白原血症和/或血小板减少症。